Arctic Vision expands ophthalmic capabilities through strategic MDCO Technology acquisition

CHINA—Arctic Vision has finalized an agreement to acquire the ophthalmic device business of MDCO Technology, marking a significant expansion in the company’s capabilities within the eye care sector.

The deal brings together MDCO’s specialized device manufacturing expertise with Arctic Vision’s pharmaceutical research and development strengths.

Comprehensive integration of device platforms

The acquisition encompasses MDCO’s complete portfolio of ophthalmic devices, including intraocular lenses (IOL), implantable contact lenses (Phakic Lens), and various refractive device platforms.

Arctic Vision plans to integrate these technologies into its global innovation framework, creating a more comprehensive approach to ophthalmic solutions.

The combined capabilities will allow the company to address a broader spectrum of eye care needs, from surgical interventions to advanced vision correction technologies.

MDCO brings nearly two decades of specialized experience in cataract and myopia-correction solutions to the partnership.

The company has developed significant expertise in materials science and precision-moulding technologies, which have become the foundation of its product development approach.

These technical capabilities complement Arctic Vision’s existing pharmaceutical research, creating opportunities for innovation that spans both drug-based and device-based treatments.

Strategic alignment with growth goals

The transaction supports Arctic Vision’s broader strategy to expand its presence in ophthalmic areas with significant unmet medical needs.

By combining MDCO’s advanced device engineering and manufacturing capabilities with its own research and development infrastructure, Arctic Vision aims to accelerate the development of new patient solutions.

The company’s existing R&D strengths in retinal diseases, ocular surface conditions, and neuro-ophthalmic disorders will now be enhanced by device innovation capabilities.

Arctic Vision expects to build a diversified portfolio that leverages the strengths of both organizations.

This approach allows the company to pursue therapeutic opportunities across multiple treatment modalities, offering both pharmaceutical and device-based interventions to eye care professionals and their patients.

Operational Structure and Geographic Presence

Following the completion of the transaction, MDCO will function as a wholly owned subsidiary within the Arctic Vision corporate structure.

The combined organization will maintain a multi-location operational model designed to maximize the strengths of each geographic hub.

Shanghai will serve as the center for biopharmaceutical research activities and regulatory affairs, providing a foundation for drug development and compliance with regional healthcare authorities.

Hangzhou will house the device-focused operations, including research and development, manufacturing facilities, and commercial management for the device business.

MDCO’s existing Hangzhou site already serves as the operational hub for its manufacturing, R&D, and commercial activities.

California will contribute design capabilities and facilitate global collaboration initiatives, connecting the organization with international partners and markets.

Leadership vision for long-term growth

Dr. Eddy Wu, founder, chairman, and CEO of Arctic Vision, characterized the acquisition as a pivotal milestone in the company’s long-term growth trajectory.

 He emphasized that the integration of MDCO’s device platforms with Arctic Vision’s pharmaceutical innovation creates a comprehensive ophthalmic innovation ecosystem.

This ecosystem combines scientific excellence with advanced manufacturing capabilities and commercial scale, positioning the company to serve a larger patient population.

Dr. Wu also highlighted that the transaction strengthens the company’s foundation for future growth opportunities.

The expanded structure prepares Arctic Vision for broader participation from global investors and positions the organization for potential capital-market opportunities.

The enhanced capabilities will enable the company to extend its reach to more patients while delivering greater impact throughout the ophthalmology community on a worldwide scale.